Emergency BU Alert Boston University's Charles River and Medical Center Campuses will be closed all day Tuesday, January 27, 2015. BU Medical Campus CLOSED Tuesday, Jan. 27, 2015 Boston University Medical Campus will be closed Tuesday, Jan. 27. All normal academic and administrative activities have been canceled. Employees in essential services should report as scheduled. Essential services include, but are not limited to Public Safety, Facilities Management, Emergency Patient Treatment, Office of Environmental Health and Safety, Occupational and Environmental Medicine, and Mail Service. Medical, PA and GMS students who are assigned to inpatient services or clinics are expected to be present, if possible. Students who are assigned to outpatient services should check with their course directors or the policy at the clinical site. For the very latest information, please go to BU Today at http://www.bu.edu/today and the Emergency Communications page at http://www.bu.edu/ehs/comm

Edward Damiano Ph.D.

Biomedical Engineering

Office: ERB 701-B
Phone: (617) 353-9493
Email: edamiano@bu.edu


Dr. Damiano’s research group is engaged in research that combines fluid dynamics with intravital microscopy to study blood flow in microcirculation and to elucidate mechanisms by which the lining of blood vessels determine vascular health and disease.  In particular, his laboratory has been focusing on the endothelial glycocalyx, which forms a complex hydrated mesh of cell surface macromolecules that is situated at the interface between the luminal vascular wall and flowing blood. His group has developed new analytical and experimental tools to interrogate the glycocalyx in vivo and in vitro.  They have demonstrated that this layer of macromolecules extends ~500 nm from the wall of healthy blood vessels, but is significantly degraded in the presence of vascular inflammation and chronic hyperglycemia. His group is also testing therapeutic interventions aimed at preventing and counteracting the damage to the glycocalyx, which may underlie vascular pathologies such as atherosclerosis and micro vascular complications associated with diabetes.  In addition to this research, he is also personally committed to creating and integrating closed-loop control technologies for automatically regulating blood glucose in diabetes.  After testing and qualifying his group’s blood-glucose control algorithms in diabetic swine, this system became the first academically sponsored investigational device to receive FDA approval for testing in subjects with type 1 diabetes.  The first clinical trial testing of their device was recently completed, and additional trials are planned for later this year.

Affiliated Websites:

Department of Biomedical Engineering Webpage